Body mass index in postmenopausal ER-positive, HER2-negative early breast cancer: LORELEI explorat

Article metadata and bibliographic details

This PubMed record presents an exploratory analysis titled "Body mass index in postmenopausal women with estrogen receptor-positive, HER2-negative early breast cancer: An exploratory analysis of the LORELEI trial." The citation indicates publication in Eur J Cancer (2026), with DOI 10.1016/j.ejca.2026.116880 and PubMed ID 42308863. The PubMed entry classifies the item under Randomized Controlled Trial and lists an Elsevier Science full-text link as a route to the published article.

Scope and clinical question: BMI in postmenopausal ER-positive, HER2-negative early breast cancer

From the article title and PubMed classification, the analysis addresses the relationship between body mass index and outcomes or characteristics in postmenopausal women with estrogen receptor-positive (ER+), HER2-negative early-stage breast cancer. The designation "exploratory analysis" suggests a secondary or hypothesis-generating evaluation performed within the preexisting trial dataset rather than a primary prespecified endpoint; however, PubMed content shown here does not provide the analysis objectives, endpoints, or hypotheses tested.

LORELEI trial context and study designation

The work is described as an analysis of the LORELEI trial. The PubMed entry does not include trial-level details (for example, original trial interventions, primary endpoints, enrollment criteria, or randomization schema) within the provided excerpt. The presence of the randomized controlled trial label on PubMed indicates the underlying dataset derives from a randomized study, but further context must be sought in the full-text article or trial registry.

Authors, affiliations and collaboration

A broad international author list is provided on the PubMed page, with affiliations spanning academic cancer centers and cooperative groups across Europe and industry representation from Genentech, Inc. The author group includes clinical investigators and trial collaborators from institutions such as Université libre de Bruxelles, Gustave Roussy, Vall d'Hebrón Institute of Oncology, Austrian Breast and Colorectal Cancer Study Group (ABCSG), and others. This indicates a multicenter collaboration underlying the analysis.

Available report content on PubMed (what is present)

The PubMed excerpt supplied here includes the full author list with affiliations, publication metadata (journal, year, DOI, PubMed ID), and a link to full-text options. It identifies the work as an exploratory analysis of BMI within the LORELEI trial population (postmenopausal women with ER-positive, HER2-negative early breast cancer).

Missing details in the PubMed entry (what is not reported)

Important methodological and outcome details are not present in the PubMed excerpt provided. Specifically, the following items were not reported in the content available here:

• Abstract text describing background, objectives, and conclusions
• Sample size and BMI categorization or distribution
• Statistical methods, covariates, and adjustments used in analyses
• Primary and secondary outcome measures and time points
• Numerical results, effect sizes, confidence intervals, and p values
• Safety data or adverse-event reporting
• Authors' interpretation, limitations, and clinical recommendations

Because these elements are absent from the PubMed content shown, readers cannot reliably infer study findings or their clinical significance from this record alone.

Implications for clinicians and researchers

The topic—BMI in postmenopausal patients with ER-positive, HER2-negative early breast cancer—is clinically relevant given interest in body composition as a prognostic and predictive factor. However, the PubMed entry does not provide results or conclusions; therefore:

• Clinicians should not change clinical practice or management based on the bibliographic listing alone.
• Researchers and guideline developers should consult the published full text for methodology and outcomes before integrating findings into evidence syntheses or recommendations.
• The exploratory nature of the analysis implies results may be hypothesis-generating and may require confirmation in independent cohorts or prospective studies; specific statements about reproducibility or strength of evidence are not available in the PubMed excerpt.

How to access full text and next steps

The PubMed page lists a direct Elsevier Science full-text link. To obtain complete information—including the abstract, methods, statistical analysis, results, tables, figures, and authors' conclusions—consult the full-text article via the publisher link, institutional access, or interlibrary services. If unavailable, contact the corresponding author as listed in the article for clarifications.

Note on source limitations

This summary and editorial rewrite are strictly limited to information presented in the PubMed record content provided. Detailed study findings, numerical data, and the authors' conclusions were not included in that content and therefore are not reported here. For complete and actionable clinical information, readers must review the published article.